These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35762631)
1. Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases. So H; Tam LS Curr Opin Rheumatol; 2022 Jul; 34(4):203-208. PubMed ID: 35762631 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease in spondyloarthritis: a narrative review of risk factors and the effect of treatments. Sen R; Caplan L; Danila MI Curr Opin Rheumatol; 2024 Mar; 36(2):95-107. PubMed ID: 38126207 [TBL] [Abstract][Full Text] [Related]
3. [Nonsteroidal anti-inflammatory drugs in the treatment of anterior uveitis associated with spondyloarthritis]. Razumova IY; Godzenko AA Vestn Oftalmol; 2020; 136(6):70-77. PubMed ID: 33084282 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Hermann M Curr Rheumatol Rep; 2009 Feb; 11(1):31-5. PubMed ID: 19171109 [TBL] [Abstract][Full Text] [Related]
5. Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis. da Cruz Lage R; Marques CDL; Oliveira TL; Resende GG; Kohem CL; Saad CG; Ximenes AC; Gonçalves CR; Bianchi WA; de Souza Meirelles E; Keiserman MW; Chiereghin A; Campanholo CB; Lyrio AM; Schainberg CG; Pieruccetti LB; Yazbek MA; Palominos PE; Goncalves RSG; Assad RL; Bonfiglioli R; Lima SMAAL; Carneiro S; Azevedo VF; Albuquerque CP; Bernardo WM; Sampaio-Barros PD; de Medeiros Pinheiro M Adv Rheumatol; 2021 Jan; 61(1):4. PubMed ID: 33468245 [TBL] [Abstract][Full Text] [Related]
6. Pregnancy & neonatal outcomes in spondyloarthritis. Maguire S; Molto A Best Pract Res Clin Rheumatol; 2023 Sep; 37(3):101868. PubMed ID: 37652852 [TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. Braun J; Baraliakos X; Westhoff T Semin Arthritis Rheum; 2020 Apr; 50(2):285-288. PubMed ID: 31439354 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Poddubnyy D; van der Heijde D Rheum Dis Clin North Am; 2012 Aug; 38(3):601-11. PubMed ID: 23083758 [TBL] [Abstract][Full Text] [Related]
9. Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications. Varkas G; Van Praet L; Cypers H; Elewaut D Z Rheumatol; 2013 Aug; 72(6):524-9. PubMed ID: 23756592 [TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
11. Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus . Mazhar F; Haider N; Sultana J; Akram S; Ahmed Y Int J Clin Pharmacol Ther; 2018 Feb; 56(2):64-71. PubMed ID: 29208206 [TBL] [Abstract][Full Text] [Related]
12. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173 [TBL] [Abstract][Full Text] [Related]
13. The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity? Omarjee L; Jaquinandi V; Mahe G J Transl Med; 2017 Dec; 15(1):255. PubMed ID: 29246242 [TBL] [Abstract][Full Text] [Related]
15. Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Gargiulo G; Capodanno D; Longo G; Capranzano P; Tamburino C Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1185-203. PubMed ID: 25220474 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Zingler G; Hermann B; Fischer T; Herdegen T Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1479-1492. PubMed ID: 27575590 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Joshi GP; Gertler R; Fricker R Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885 [TBL] [Abstract][Full Text] [Related]